AJMC® in the Press, February 17, 2023

Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent, non-del(5q) lower-risk myelodysplastic syndrome that is relapsed or refractory to erythropoiesis stimulating agents, according to findings from the phase 3 IMerge trial.

On this episode of Managed Care Cast, we speak with the lead researcher from a study published in the May 2023 issue of The American Journal of Managed Care® about the impact of low-income subsidies on the uptake and equitable use of expensive orally administered antimyeloma therapy.

Issue will feature guest editor, Sunny C. Lin, Ph.D., of Washington University in St. Louis

On this episode of Managed Care Cast, we feature several leaders in diversity, equity, and inclusion advancing health equity in their respective organization’s policy and practice initiatives.

Posters presented at the SLEEP 2023 conference showed that transition between medications was easy but 1 medication felt more effective to patients.

In a review of adults with type 1 diabetes (T1D), having a body mass index (BMI) <18.5 kg/m2 increased the risk of all-cause mortality by 3.4 times compared with normal BMI.